Randomized trial · people
Exenatide, alone or with dapagliflozin, improved blood sugar in PCOS
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In this trial, weekly exenatide paired with dapagliflozin gave the broadest metabolic gains in women with PCOS and obesity, and the blood sugar gains held up even when another drug matched its weight loss.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 119
- Published
- 2021
- Journal
- J Clin Endocrinol Metab
What they tested
The team compared five drug options to see how each changed metabolism, body makeup and sex hormones in women with obesity and polycystic ovary syndrome (PCOS).
How the study was done
A single-blinded randomized trial in 119 women without diabetes, aged 18-45, with a BMI above 30 and below 45 and PCOS. For 24 weeks, each woman took one of five options: once-weekly exenatide (the 2 mg weekly arm), dapagliflozin 10 mg daily, both together, dapagliflozin with extended-release metformin, or phentermine/topiramate.

Model. Individual results vary.
What they found
Exenatide plus dapagliflozin and phentermine/topiramate led to the most loss of weight, waist size and total body fat measured by DXA, a body scan. Phentermine/topiramate matched the combination on BMI and waist loss. Even so, only exenatide plus dapagliflozin and exenatide alone significantly improved mean blood glucose and measures of insulin sensitivity and insulin secretion from oral glucose tolerance tests. All five options lowered fasting glucose, testosterone, free androgen index (a measure of active male-type hormones) and blood pressure.
What it doesn’t show
The trial ran 24 weeks and had no placebo arm, so every group got an active drug. It included only women without diabetes who had obesity and PCOS, so it doesn't show how these drugs work in other groups.
The paper
Elkind-Hirsch et al. Exenatide, Dapagliflozin, or Phentermine/Topiramate Differentially Affect Metabolic Profiles in Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2021.
The compound
More studies on Exenatide
- Exenatide: no cognitive benefit in mild cognitive impairmentRandomized trial · people · 2024
- Exenatide: lower intracranial pressure in IIH over 12 weeksRandomized trial · people · 2023
- Exenatide did not cut heavy drinking days in alcohol use disorderRandomized trial · people · 2022
- Exenatide: 29.2% spontaneous pregnancy vs 14.7% on metformin in PCOSRandomized trial · people · 2022
- Exenatide plus dapagliflozin: UACR fell 39.6% vs 11.0% on placeboRandomized trial · people · 2021
- Exenatide ER: 0.9% HbA1c drop vs 1.5% with semaglutide in SUSTAIN 3Randomized trial · people · 2018
- Every study on Exenatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.